In this news episode of Trending Health, Mindy McGrath and Everly Petruzzelli break down the evolving regulatory landscape at the FDA and what it means for life sciences leaders. This episode covers:

• Staff changes to the FDA and approval pathway pilot programs
• Rising scrutiny on trial design — especially in rare disease
• The FDA’s firmer stance on compounded GLP-1s as shortages ease

From regulatory unpredictability to access, pricing, and portfolio risk, we explore how life sciences leaders should adapt in a more dynamic regulatory environment.

For additional discussion and to see the sources referenced in this episode, check out TrendingHealth.com.

Panel – Mindy McGrath & Everly Petruzzelli

Recording & Editing – Mike Liberto & Rachel Skonecki

Source Links:

• J&J\’s Tecvayli-Darzalex multiple myeloma combo takes home FDA\’s 3rd national priority nod
• FDA slammed over rare disease drug decisions
• Disc\’s rare disease drug hit by FDA rejection
• FDA rejects Biohaven approval request for troriluzole, triggering cost cutting
• FDA reverses course, agrees to review Moderna’s flu vaccine
• FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters

As 2026 begins, pharma leaders are placing sharper bets earlier while navigating increasing pressure across pricing, access, and evidence. In this episode, Matt Riordan, Group President, Putnam, shares a candid, executive-level view of what leaders are prioritizing this year, where confidence is high, and where blind spots may limit impact. Drawing on real-world leadership conversations, the discussion explores how access and evidence expectations are shifting upstream and what it takes to pressure-test assumptions, align strategy earlier, and lead with greater clarity in 2026.

Panel – Mindy McGrath, Matt Riordan

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com.

As we kick off 2026, Mindy sits down with Inizio Ignite Global President, Remco op den Kelder, to discuss the industry forces shaping the year ahead for life sciences companies.

Panel – Mindy McGrath, Remco op den Kelder

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com.